Promising Preclinical Evidence of Skeletal Muscle Regenerator SAT-3247: Frank Gleeson
March 26th 2024The president and chief executive officer of Satellos Bioscience provided an overview of the previously observed preclinical data supporting SAT-3247 as a potential therapy for muscular dystrophies. [WATCH TIME: 4 minutes]